Compare BIO-TECHNE Corp (TECH) vs Wheaton Precious Metals Corp (WPM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Wheaton Precious Metals Corp — how do they compare? BIO-TECHNE Corp trades at $72.39 (market cap $11.34B), while Wheaton Precious Metals Corp trades at $158 (market cap $70.35B). The key difference: Wheaton Precious Metals Corp is far larger — about 6.2× BIO-TECHNE Corp's market cap, and Wheaton Precious Metals Corp pays the higher dividend (0.5%). Which is the better fit depends on your goals.
| TECH | WPM | |
|---|---|---|
Market Cap | $11.34B | $70.35B |
Sector | Health | Basic Materials |
52-Week High | $72.48 | $165.72 |
52-Week Low | $43.31 | $94.37 |
Enterprise Value | $11.36B | $72.23B |
Dividend Yield | 0.44% | 0.5% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.31, down 0.17% on the day, with a neutral technical signal and mixed earnings history. The stock is near the consensus price target of $71.86, with a pending acquisition by Merck KGaA at $73.00 per share. Recent Q4 2026 revenue beat estimates, but net income margin compression from 25.09% in 2023 to 14.96% in 2026 highlights profitability challenges. Operating cash flow remains stable around $290M, supporting dividend payments.
The outlook is balanced, with upside capped by the acquisition offer but supported by solid cash flow and analyst hold ratings. Risks include shareholder litigation and integration uncertainties post-acquisition. Earnings growth in diagnostics and spatial biology segments is a key catalyst, though high P/E of 62.33 suggests elevated expectations.
Wheaton Precious Metals (WPM) trades at $155.11, up 0.08% on the day, with a bullish technical signal from moving averages and strong fundamental performance. Recent earnings beats, including Q2 2026 EPS of $1.19 versus $1.15 expected, and record revenue of $2.31 billion in 2025 underscore robust operational momentum. The company's royalty and streaming model continues to deliver high margins, with a net income margin of 64.66% in 2025.
The outlook remains positive, supported by an 80% analyst buy rating and a consensus price target of $161.75, though risks include exposure to commodity price volatility and significant capital expenditures projected for 2026. The stock's current valuation multiples, such as a P/E of 34.41, reflect premium pricing relative to historical norms.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Wheaton Precious Metals Corp
Wheaton Precious Metals Corp is a precious metal streaming company. The company has entered into over 20 long-term purchase agreements with 17 different mining companies, for the purchase of precious metals and cobalt. It has streaming agreements covering approximately 19 operating mines and 9 development stage projects. The company's projects include Vale's Salobo mine and silver streams on Glencore's Antamina mine and Goldcorp's Penasquito mine.
Read more on WPM →
